within Pharmacolibrary.Drugs.ATC.D;

model D07AC09
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0014,
    adminDuration  = 600,
    adminMass      = 1.0 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0032,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.002,
    k12             = 41,
    k21             = 41
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D07AC09</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Budesonide is a synthetic corticosteroid with potent glucocorticoid activity, used primarily as an anti-inflammatory agent in the treatment of conditions such as asthma, chronic obstructive pulmonary disease (COPD), and several dermatological disorders. It is approved for medical use today and can be administered by inhalation, orally, rectally, or topically. In contexts of the ATC code D07AC09, it is primarily used as a topical preparation for skin disorders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for adult healthy volunteers administered budesonide topically; published values from population PK analyses and clinical studies.</p><h4>References</h4><ol><li><p>Szefler, SJ (1999). Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. <i>The Journal of allergy and clinical immunology</i> 104(4 Pt 2) 175–183. DOI:<a href=\"https://doi.org/10.1016/s0091-6749(99)70059-x\">10.1016/s0091-6749(99)70059-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10518844/\">https://pubmed.ncbi.nlm.nih.gov/10518844</a></p></li><li><p>Abdalla, MI, &amp; Herfarth, H (2016). Budesonide for the treatment of ulcerative colitis. <i>Expert opinion on pharmacotherapy</i> 17(11) 1549–1559. DOI:<a href=\"https://doi.org/10.1080/14656566.2016.1183648\">10.1080/14656566.2016.1183648</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27157244/\">https://pubmed.ncbi.nlm.nih.gov/27157244</a></p></li><li><p>Tambucci, R, et al., &amp; De Angelis, P (2023). Oral Viscous Budesonide in Children With Eosinophilic Esophagitis After Repaired Esophageal Atresia: A Clinical Trial. <i>Journal of pediatric gastroenterology and nutrition</i> 77(2) 249–255. DOI:<a href=\"https://doi.org/10.1097/MPG.0000000000003830\">10.1097/MPG.0000000000003830</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37195886/\">https://pubmed.ncbi.nlm.nih.gov/37195886</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D07AC09;
